Key result
Control of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) expression and activity represents a potential therapeutic target to retard ventricular remodeling in heart failure.
Matrix metalloproteinases and their inhibitors play a key role in left ventricular remodeling in heart failure, representing a potential novel therapeutic target.
No takes yet. Share an insight, caveat, or question.
Supports MMP/TIMP modulation as research priority in HF; prospective trials needed before clinical adoption.
Francis G. Spinale (1999) conducted a review in Congestive heart failure. Matrix metalloproteinase (MMP) inhibitors was evaluated. Control of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) expression and activity represents a potential therapeutic target to retard ventricular remodeling in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: